Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
NEW YORK — Four finalists are making presentations this week in a review for Lantus, a diabetes drug from Aventis Pharmaceuticals, sources said.
Billings on the global account, which includes both creative and media duties, have not been determined. Sources, however, pegged them at $100 million.
The presentations are taking place on Monday and Tuesday at the client’s U.S. headquarters in Bridgewater, N.J. The finalists are Interpublic Group’s McCann-Erickson, Omnicom Group’s TBWA Worldwide, Havas’ Euro RSCG and the WPP Group team of Young & Rubicam, Burson-Marsteller and Mediaedge:cia, said sources.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in